Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 4/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.65 |
| ▸ | F2 | P00734 | 4/20 | 0.65 |
| ▸ | PLG | P00747 | 2/20 | 0.65 |
| ▸ | C1S | P09871 | 1/20 | 0.65 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 3/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118456 | 0.86 | PRSS1 (0.64) | PRSS1PRSS2PRSS3F2LOXL2 | |
| SCHEMBL29182121 | 0.82 | FOLH1 (0.61) | — | |
| SCHEMBL4461405 | 0.81 | PRSS1 (0.61) | PRSS1PRSS2PRSS3F2PLG | |
| SCHEMBL1329642 | 0.79 | F2 (1.00) | PRSS1PRSS2PRSS3F2PLG | |
| SCHEMBL27595727 | 0.77 | PRSS1 (0.65) | PRSS1PRSS2PRSS3F2PLG | |
| SCHEMBL8556448 | 0.77 | ALDH1A1 (0.61) | PRSS1PRSS2PRSS3F2LOXL2 | |
| Acetic Acid SCHEMBL27805057 | 0.77 | PRSS1 (0.80) | PRSS1PRSS2PRSS3F2LOXL2 | |
| Acetic Acid SCHEMBL2548755 | 0.77 | PRSS1 (0.80) | PRSS1PRSS2PRSS3F2LOXL2 | |
| SCHEMBL7118443 | 0.77 | ITGB3 (0.64) | PRSS1PRSS2PRSS3F2LOXL2 | |
| SCHEMBL7083845 | 0.76 | MEN1 (0.56) | PRSS1PRSS2PRSS3LOXL2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-20220054479-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885PRSS2 665/4885PRSS3 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.